Pathological analysis of side effecte to the treatment of adult T-cell leukemia

Pathological analysis of side effecte to the treatment of adult T-cell leukemia - Pathological analysis of side effecte to the treatment of adult T-cell leukemia

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017469

Enrollment

Registered

2015-05-08

Start date

2014-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult T-cell leukemia

Interventions

Anti-CCR4 antibody drug administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients ,who has the announcement of the ATL, with relapsed or refractory of CCR4-positive adult T-cell leukemia lymphoma and relapsed or refractory of CCR4-positive cutaneous T-cell lymphoma (5 cases) with an anti-CCR4 antibody drug administration's with relapsed or refractory of CCR4-positive adult T-cell leukemia lymphoma and relapsed or refractory of CCR4-positive cutaneous T-cell lymphoma (5 cases) with an anti-CCR4 antibody drug administration's

Exclusion criteria

Exclusion criteria: Minor Adult person who dose not have enough judgment Unconscious adult person Adult person who required attention for thedisease notification

Design outcomes

Primary

Measure	Time frame
Analysis of the immune response of the anti-CCR4 antibody drug proceeds for the ATL, new side reaction diagnostic and therapeutic methods is likely to be developed.	—

Countries

Japan

Contacts

Public ContactYugo Ashino

Tohoku University Division of Emerging Infectious Diseases, Graduate School of Medicine

ya82@rid.med.tohoku.ac.jp022-717-8220

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026